Catalyst Biosciences, Inc.
611 Gateway Blvd.
Suite 710
South San Francisco
California
94080
United States
Tel: 650-871-0761
Website: http://www.catalystbiosciences.com/
Email: info@catbio.com
About Catalyst Biosciences, Inc.
We are a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hemostasis and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (“AMD”). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
137 articles with Catalyst Biosciences, Inc.
-
Catalyst Biosciences Announces Positive Factor IX Clinical Data
9/6/2017
-
Catalyst Biosciences Reports Second Quarter 2017 Financial Results And Provides Subcutaneous (SQ) Hemophilia Program Update
8/3/2017
-
Financial Milestone Achieved In Catalyst Biosciences' Subcutaneous Factor IX Program
7/6/2017
-
Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation In Europe
6/28/2017
-
Catalyst Biosciences Announces Achievement Of Stable Normal Factor IX Blood Levels In A Preclinical Subcutaneous Dosing Model
6/26/2017
-
Catalyst Biosciences And ISU Abxis Complete Dosing Of First Patient Cohort In Hemophilia B Clinical Trial
6/14/2017
-
Catalyst Biosciences Announces Presentations On Its Next-Generation Subcutaneous Hemophilia Product Candidates At The 2017 International Society On Thrombosis And Haemostasis (ISTH) Meeting
6/8/2017
-
Catalyst Biosciences’ Factor IX Recommended For Orphan Drug Designation In Europe
5/31/2017
-
Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
5/11/2017
-
Catalyst Biosciences Announces Closing Of A $20.7 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option
4/13/2017
-
Key Milestone Reached In Catalyst Biosciences’s Subcutaneous Factor IX Program
4/11/2017
-
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering
4/7/2017
-
Why Catalyst Biosciences Nearly Tripled
3/29/2017
-
Catalyst Biosciences Announces IND Approval In South Korea For Next-Generation Subcutaneous Factor IX Program
3/28/2017
-
Catalyst Biosciences Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
3/8/2017
-
Catalyst Biosciences Announces Promotion Of Andrew Hetherington To SVP Of Technical Operations
2/16/2017
-
Catalyst Biosciences Highlights Hemophilia Clinical Development Plans At The 19th Annual BIO CEO & Investor Conference
2/14/2017
-
Catalyst Biosciences To Present At 19th Annual BIO CEO & Investor Conference
2/3/2017
-
Catalyst Biosciences Announces Positive Preclinical Data Of Subcutaneously Dosed Coagulation Factors VIIa And IX At EAHAD Annual Congress
2/1/2017
-
Catalyst Biosciences Announces Multiple Data Presentations At The 2017 Congress Of The European Association Of Haemophilia And Allied Disorders
1/26/2017